bioAffinity Tech (BIAF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIAF SEC filings page.
bioAffinity Tech (BIAF) reported $5.9M in revenue over the twelve months to Jun 30, 2026, down 23.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing inflows are supporting a cash-consuming operating model as revenue contracts and losses widen.
Revenue contracted in FY2025, yet operating losses consumed a larger share of sales than in FY2024, pointing to limited cost flexibility. SG&A stayed near$10.0M while operating cash flow reached-$9.3M , linking the margin deterioration to continuing cash needs rather than an accounting-only charge.
Net loss reached
Financing cash flow supplied
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of bioAffinity Tech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
bioAffinity Tech held $6.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and bioAffinity Tech scores 26/100 among other emerging companies.
bioAffinity Tech had 4M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and bioAffinity Tech scores 83/100 among other emerging companies.
bioAffinity Tech spent $1.4M on research and development in fiscal year 2025, which was 8.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and bioAffinity Tech scores 32/100 among other emerging companies.
bioAffinity Tech reported revenue of $6.2M in fiscal year 2025, against $9.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and bioAffinity Tech scores 27/100 among other emerging companies.
bioAffinity Tech's operations used $9.3M of cash in fiscal year 2025, against $7.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and bioAffinity Tech scores 27/100 among other emerging companies.
bioAffinity Tech's cash, cash equivalents and investments came to $6.4M at the end of fiscal year 2025, against $3.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and bioAffinity Tech scores 72/100 among other emerging companies.
bioAffinity Tech scores -9.84, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.3M) relative to total liabilities ($3.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
bioAffinity Tech passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
bioAffinity Tech reported a net loss of $14.9M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
bioAffinity Tech reported an operating loss of $10.6M against $44K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
bioAffinity Tech generated $1.5M in revenue in Q2 2026. This represents an increase of 19.0% from the same quarter a year earlier. Against the prior quarter it is up 11.8%.
bioAffinity Tech's EBITDA was -$3.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.3% from the same quarter a year earlier. Against the prior quarter it is up 6.5%.
bioAffinity Tech reported -$3.4M in net income in Q2 2026. This represents an increase of 17.1% from the same quarter a year earlier. Against the prior quarter it is up 7.3%.
bioAffinity Tech earned -$0.64 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 21.0%.
Cash & Balance Sheet
bioAffinity Tech recorded an outflow of $3.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 23.7% from the same quarter a year earlier. Against the prior quarter it is down 1.8%.
bioAffinity Tech held $2.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
bioAffinity Tech's ROE was -89.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 10.2 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
bioAffinity Tech invested $362K in research and development in Q2 2026. This represents an increase of 16.1% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.
bioAffinity Tech invested $90K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 570.1% from the same quarter a year earlier. Against the prior quarter it is up 1488.7%.
Not reported for Q2 2026.
BIAF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M+19.0% | $1.4M-27.1% | $1.6M-27.8% | $1.4M-38.5% | $1.3M-47.1% | $1.9M-23.0% | $2.2M-70.9% | $2.4M+682.8% |
| R&D Expenses | $362K+16.1% | $350K-4.8% | $374K-4.3% | $331K+20.4% | $311K-22.6% | $367K-6.7% | $391K-9.7% | $274K-16.9% |
| SG&A Expenses | $2.9M+29.1% | $3.2M+32.2% | $3.0M+4.0% | $2.2M-6.6% | $2.2M-10.4% | $2.5M+12.2% | $2.9M+31.9% | $2.4M+16.8% |
| Operating Income | -$3.3M-32.6% | -$3.6M-37.7% | -$3.1M-6.5% | -$2.3M-16.2% | -$2.5M-20.5% | -$2.6M-35.1% | -$2.9M-25.8% | -$2.0M+14.0% |
| EBITDA | -$3.3M-36.3% | -$3.5M-41.7% | -$3.0M-7.9% | -$2.2M-19.6% | -$2.4M-24.0% | -$2.5M-37.7% | -$2.8M-27.3% | -$1.8M+18.5% |
| Interest Expense | $12K+11.7% | $15K-4.9% | $13K-47.8% | $5K-75.2% | $10K-53.0% | $15K-34.2% | $25K-1.1% | $22K+146.2% |
| Income Tax | N/A | N/A | $3K | $3K+24.3% | $29K+434.9% | $9K+136.8% | $0-100.0% | $3K+11.6% |
| Net Income | -$3.4M+17.1% | -$3.6M-36.5% | -$3.1M-5.7% | -$5.1M-152.4% | -$4.1M-92.4% | -$2.7M-35.6% | -$3.0M-25.0% | -$2.0M+12.7% |
| EPS (Basic) | -$0.64+87.4% | -$0.81+83.1% | -$1.11+82.3% | -$4.74+2.1% | -$5.07-2568.4% | -$4.80-2300.0% | -$6.28-2315.4% | -$4.84-1761.5% |
| EPS (Diluted) | -$0.64 | -$0.81 | -$1.11 | -$4.74 | -$5.07 | -$4.80 | -$6.28 | -$4.84 |
| Diluted Shares (Avg) | 5M | 4M | N/A | 1M | 800,637 | 541,841 | N/A | 412,936 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BIAF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M+60.4% | $7.9M+43.2% | $11.0M+68.3% | $11.5M+76.2% | $4.8M-28.6% | $5.5M-31.1% | $6.5M-20.8% | $6.6M-35.7% |
| Current Assets | $3.9M+131.6% | $4.3M+132.9% | $7.6M+180.7% | $8.6M+237.9% | $1.7M-37.7% | $1.9M-52.6% | $2.7M-32.2% | $2.5M-57.6% |
| Cash & Equivalents | $2.4M+202.6% | $3.1M+596.7% | $6.4M+483.5% | $7.7M+913.7% | $803K+0.2% | $445K-81.9% | $1.1M-60.8% | $757K-83.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $82K+87.3% | $78K+100.8% | $54K+94.0% | $35K+38.9% | $44K+47.7% | $39K+308.8% | $28K+49.4% | $25K+156.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M+22.3% |
| Total Liabilities | $3.9M-44.1% | $4.3M+4.3% | $3.7M-5.8% | $2.6M-22.9% | $6.9M+113.7% | $4.1M+47.1% | $3.9M+16.2% | $3.4M+7.4% |
| Current Liabilities | $2.7M+3.6% | $3.2M-6.7% | $2.9M-6.4% | $2.4M-5.3% | $2.6M+11.3% | $3.4M+92.8% | $3.1M+38.1% | $2.5M+27.2% |
| Non-Current Liabilities | $1.2M-72.8% | $1.1M+58.7% | $777K-3.7% | $285K-69.7% | $4.3M+379.2% | $692K-32.2% | $807K-27.9% | $940K-24.0% |
| Total Equity | $3.8M+276.4% | $3.6M+153.4% | $7.3M+179.7% | $8.9M+185.2% | -$2.1M-162.2% | $1.4M-72.6% | $2.6M-46.4% | $3.1M-55.4% |
| Retained Earnings | -$75.6M-25.2% | -$72.2M-28.2% | -$68.6M-27.8% | -$65.4M-29.1% | -$60.4M-24.0% | -$56.3M-20.9% | -$53.6M-20.3% | -$50.7M-20.0% |
Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.
BIAF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-20.9% | -$3.2M-96.6% | -$2.6M-52.6% | -$2.5M-45.1% | -$2.6M-72.7% | -$1.6M+30.0% | -$1.7M-3.8% | -$1.7M-11.5% |
| Depreciation & Amortization | $62K-45.6% | $115K-25.9% | $124K-19.5% | $113K-25.1% | $113K-25.0% | $155K+3.3% | $154K+3.3% | $151K+162.8% |
| Stock-Based Compensation | N/A | $14K-95.6% | N/A | $67K-63.8% | $212K-26.3% | $327K+15.1% | N/A | $186K+117.8% |
| Capital Expenditures | $90K+570.1% | $6K-88.8% | $10.0% | -$4K-61.3% | $13K-52.5% | $51K+22.7% | $1-100.0% | $9K+5468.0% |
| Free Cash Flow | -$3.3M-23.7% | -$3.2M-91.0% | -$2.6M-52.6% | -$2.5M-44.5% | -$2.7M-70.5% | -$1.7M+29.1% | -$1.7M-2.9% | -$1.7M-12.1% |
| Investing Cash Flow | -$90K-570.1% | -$6K+88.8% | -$10.0% | $4K+138.7% | -$13K+52.5% | -$51K-22.7% | -$1-100.0% | -$9K+99.6% |
| Financing Cash Flow | $2.6M-13.1% | -$119K-111.5% | $1.3M-33.8% | $9.3M+458.2% | $3.0M+3412.1% | $1.0M-48.9% | $2.0M+2488.9% | $1.7M+3397.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIAF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -220.8% | -267.6% | -196.9% | -158.6% | -198.2% | -141.7% | -133.5% | -84.0% |
| Net Margin | -222.8% | -268.6% | -197.0% | -349.3% | -319.9% | -143.5% | -134.4% | -85.1% |
| Return on Equity | -89.3% | -99.6%+85.3pp | -43.1%+70.9pp | -56.7%+7.4pp | N/A | -184.8%-147.5pp | -114.0%-65.1pp | -64.1%-31.4pp |
| Return on Assets | -44.2%+41.3pp | -45.7%+2.3pp | -28.6%+16.9pp | -43.8%-13.2pp | -85.5%-53.8pp | -48.0%-23.6pp | -45.6%-16.7pp | -30.5%-8.1pp |
| Current Ratio | 1.44+0.8x | 1.36+0.8x | 2.60+1.7x | 3.65+2.6x | 0.64-0.5x | 0.55-1.7x | 0.87-0.9x | 1.02-2.0x |
| Debt-to-Equity | 1.02 | 1.17-1.7x | 0.51-1.0x | 0.30-0.8x | N/A | 2.85+2.3x | 1.50+0.8x | 1.10+0.6x |
| Asset Turnover | 0.20-0.1x | 0.17-0.2x | 0.15-0.2x | 0.13-0.2x | 0.27-0.1x | 0.330.0x | 0.34-0.6x | 0.36+0.3x |
| FCF Margin | -217.9% | -239.2% | -160.7% | -171.8% | -209.6% | -91.3%+7.9pp | -76.0%-54.5pp | -73.1% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| bioAffinity Tech BIAF | FY2025 | $6.2M | -$14.9M | N/A | $6.3M | 45/100 |
| Mainz Biomed NV MYNZ | FY2025 | $537K | -$16.2M | N/A | $10.6M | — |
| Advanced Biomed Inc. ADVB | FY2025 | N/A | -$3.3M | N/A | $14.0M | — |
| XWELL Inc XWEL | FY2025 | $29.2M | -$17.0M | -58.2% | $8.0M | 27/100 |
| Ispecimen Inc. ISPC | FY2025 | $1.9M | -$10.5M | N/A | $3.9M | 30/100 |
| Check Cap CHEK | FY2025 | N/A | $4.1M | N/A | $9.4M | — |
Where bioAffinity Tech Ranks
Frequently Asked Questions
What is bioAffinity Tech's annual revenue?
bioAffinity Tech (BIAF) reported $6.2M in total revenue for fiscal year 2025. This represents a -34.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is bioAffinity Tech's revenue growing?
bioAffinity Tech (BIAF) revenue declined by 34.2% year-over-year, from $9.4M to $6.2M in fiscal year 2025.
Is bioAffinity Tech profitable?
No, bioAffinity Tech (BIAF) reported a net income of -$14.9M in fiscal year 2025.
What is bioAffinity Tech's EBITDA?
bioAffinity Tech (BIAF) had EBITDA of -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is bioAffinity Tech's return on equity (ROE)?
bioAffinity Tech (BIAF) has a return on equity of -204.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is bioAffinity Tech's free cash flow?
bioAffinity Tech (BIAF) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is bioAffinity Tech's operating cash flow?
bioAffinity Tech (BIAF) recorded an outflow of $9.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are bioAffinity Tech's total assets?
bioAffinity Tech (BIAF) had $11.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are bioAffinity Tech's capital expenditures?
bioAffinity Tech (BIAF) invested $61K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does bioAffinity Tech spend on research and development?
bioAffinity Tech (BIAF) invested $1.4M in research and development during fiscal year 2025.
What is bioAffinity Tech's current ratio?
bioAffinity Tech (BIAF) had a current ratio of 2.60 as of fiscal year 2025, which is generally considered healthy.
What is bioAffinity Tech's debt-to-equity ratio?
bioAffinity Tech (BIAF) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is bioAffinity Tech's return on assets (ROA)?
bioAffinity Tech (BIAF) had a return on assets of -136.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is bioAffinity Tech's P/E ratio?
bioAffinity Tech (BIAF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $6.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is bioAffinity Tech's price-to-sales ratio?
bioAffinity Tech (BIAF) trades at 1.1x sales, its market capitalization divided by revenue of $5.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $6.3M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does bioAffinity Tech's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, bioAffinity Tech (BIAF) held $6.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.3M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is bioAffinity Tech's Altman Z-Score?
bioAffinity Tech (BIAF) has an Altman Z-Score of -9.84, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is bioAffinity Tech's Piotroski F-Score?
bioAffinity Tech (BIAF) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are bioAffinity Tech's earnings high quality?
bioAffinity Tech (BIAF) reported a net loss of $14.9M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can bioAffinity Tech cover its interest payments?
bioAffinity Tech (BIAF) reported an operating loss of $10.6M against $44K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is bioAffinity Tech?
bioAffinity Tech (BIAF) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.